These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38934860)

  • 21. Different NT-proBNP circulating levels for different types of cardiac amyloidosis.
    Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Senile systemic amyloidosis: clinical features at presentation and outcome.
    Pinney JH; Whelan CJ; Petrie A; Dungu J; Banypersad SM; Sattianayagam P; Wechalekar A; Gibbs SD; Venner CP; Wassef N; McCarthy CA; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD; Lachmann HJ
    J Am Heart Assoc; 2013 Apr; 2(2):e000098. PubMed ID: 23608605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization.
    Granstam SO; Rosengren S; Vedin O; Kero T; Sörensen J; Carlson K; Flachskampf FA; Wikström G
    Amyloid; 2013 Mar; 20(1):27-33. PubMed ID: 23339421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
    Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm.
    Inomata T; Tahara N; Nakamura K; Endo J; Ueda M; Ishii T; Kitano Y; Koyama J
    ESC Heart Fail; 2021 Aug; 8(4):2647-2659. PubMed ID: 34137515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.
    Siddiqi OK; Mints YY; Berk JL; Connors L; Doros G; Gopal DM; Kataria S; Lohrmann G; Pipilas AR; Ruberg FL
    Amyloid; 2022 Jun; 29(2):71-78. PubMed ID: 35083944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac sympathetic denervation in wild-type transthyretin amyloidosis.
    Gimelli A; Aimo A; Vergaro G; Genovesi D; Santonato V; Kusch A; Emdin M; Marzullo P
    Amyloid; 2020 Dec; 27(4):237-243. PubMed ID: 32441155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
    Yunis A; Doros G; Luptak I; Connors LH; Sam F
    Am J Cardiol; 2019 Jul; 124(1):122-130. PubMed ID: 31053293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormal Coronary Flow Velocity Reserve and Decreased Myocardial Contractile Reserve Are Main Factors in Relation to Physical Exercise Capacity in Cardiac Amyloidosis.
    Clemmensen TS; Eiskjær H; Mølgaard H; Larsen AH; Soerensen J; Andersen NF; Tolbod LP; Harms HJ; Poulsen SH
    J Am Soc Echocardiogr; 2018 Jan; 31(1):71-78. PubMed ID: 29111120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).
    Ladefoged B; Clemmensen T; Dybro A; Hartig-Andreasen C; Kirkeby L; Gormsen LC; Bomholt P; Gillmore J; Poulsen SH
    ESC Heart Fail; 2023 Feb; 10(1):234-244. PubMed ID: 36193570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic significance of central hemodynamics in patients with cardiac amyloidosis.
    Russo C; Green P; Maurer M
    Amyloid; 2013 Dec; 20(4):199-203. PubMed ID: 23885891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.
    Law S; Petrie A; Chacko L; Cohen OC; Ravichandran S; Gilbertson JA; Rowczenio D; Wechalekar AD; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Fontana M; Gillmore JD
    Heart; 2022 Mar; 108(6):474-478. PubMed ID: 33990410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of extent and distribution of left ventricular hypertrophy on clinical aspects and hemodynamics of patients with hypertrophic obstructive cardiomyopathy].
    Schwartzkopff B; Schwammenthal E; Lösse B; Steeg M; Strauer BE
    Z Kardiol; 1992 Jan; 81(1):15-24. PubMed ID: 1570724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Right ventricular function and cardiopulmonary performance among patients with heart failure supported by durable mechanical circulatory support devices.
    Tran T; Muralidhar A; Hunter K; Buchanan C; Coe G; Hieda M; Tompkins C; Zipse M; Spotts MJ; Laing SG; Fosmark K; Hoffman J; Ambardekar AV; Wolfel EE; Lawley J; Levine B; Kohrt WM; Pal J; Cornwell WK
    J Heart Lung Transplant; 2021 Feb; 40(2):128-137. PubMed ID: 33281029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
    Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiology of the native heart and Thermo Cardiosystems left ventricular assist device complex at rest and during exercise: implications for chronic support.
    Branch KR; Dembitsky WP; Peterson KL; Adamson R; Gordon JB; Smith SC; Jaski BE
    J Heart Lung Transplant; 1994; 13(4):641-50; discussion 651. PubMed ID: 7947881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.